P Pu ur rp po os se e: : To evaluate the performance of the Panomat® P-10 micro-volumetric infusion pump for its use in drug administration at minimal flow rates (µL·hr -1 ; e.g., intrathecal application).
R Re es su ul lt ts s: : Steady state fluid delivery of the Panomat® P-10 infusion pump revealed less than 5% deviation to set flow rate at 10, 20, 50 and 100 µL·hr -1 , and 12% deviation at 4 µL·hr -1 . Mean zero-drug delivery time (ZDDT) after lowering the pump by 50 cm at 4 µL·hr -1 flow rate was 38.4 ± 7.3 min. At 100 µL·hr -1 and with original infusion line ZDDT was almost 20 times shorter when compared to the conventional syringe pump assembly (1.5 ± 0.5 min vs 28.5 ± 5.0 min).
C Co on nc cl lu us si io on n: : The tested Panomat® P-10 micro-volumetric pump shows an acceptable flow accuracy as well as a low susceptibility to vertical displacement, and is therefore suitable for continuous drug administration at minimal flow rates. The technology used in this pump carries potential implications for a new generation of syringe pumps. ) according to the patient's muscle tone and the side effects. 3 After the effective dose of intrathecal baclofen has been established in an individual patient, a permanent programmable pump device can be implanted into the abdominal subcutaneous tissue.
Objectif
Because of the known specific problems with conventional syringe pumps at low flow rates we evaluated the Panomat® P-10 micro-volumetric (PMV) infusion pump for intrathecal baclofen administration. The pump was originally designed for subcutaneous long-term application of insulin or iron-chelators. The manufacturer claims precise flow rates down to 1 µL·hr -1 . However, no data are available about its performance during vertical displacement which in conventional syringe infusion pumps can lead to harmful interruption of drug delivery or to bolus injection. 1, 4, 5 Fluid delivery was therefore assessed after negative vertical displacement at minimal flow rates and compared to a common conventional syringe pump infusion line assembly.
M Me et th ho od ds s
The PMV infusion pump The PMV infusion pump (Panomat® P-10, Disetronic Medical Systems AG, Burgdorf, Switzerland) is a small portable battery-operated (2 × 3 volt silver oxide cell) infusion device ( Figure 1A) . A specially designed 10-mL plastic syringe (Plastic Cartridge Set 10 mL; Disetronic Medical Systems AG, Burgdorf, Switzerland) is used. After loading the plastic cartridge with fluid the plastic filling rod ( Figure  1B uous flow rate was established by delivering a small bolus every three minutes (three-minute bolus varies according to the preset flow rate).
Conventional syringe pump infusion system
The conventional syringe pump assembly consisted of the Braun Perfusor® compact syringe pump (B. Braun, Melsungen, Germany) combined with a low compliant 50-mL infusion syringe (syringe 50-60 mL, Codan Medical Aps, Rodby, DK) and the Panomat® infusion line.
Measurements
For all measurements a gravimetric in vitro set-up was used as published earlier. 6 The distal end of the Panomat® or Injectomat® infusion line was connected to an additional stiff infusion line (PE-infusion line, Clinico Medical GmbH, Bad Hersfeld, Germany) immersed with its distal tip by 13 cm in a sampling glass filled with distilled water. A thin layer of oil covered the water surface to avoid fluid evaporation. Assuming a specific weight of distilled water of 1 g·mL -1 at room temperature fluid delivery (µL·hr -1 ) into the sampling glass was gravimetrically determined using an electronic balance (AG 204-Delta-Range®, Mettler Toledo, Schwerzenbach, Switzerland; sensitivity 0.0001 g). Data were recorded at a sample rate of one second using a purpose-written software (MCPS V2.6-CAD, Software GmbH, Mönchengladbach, Germany).
First, continuous fluid delivery of the PMV infusion pump was determined at infusion rates of 4, 10, 20, 50, and 100 µL·hr -1 each over a one-hour time period after establishing steady state flow. For the measurements the syringe outlet was adjusted to the level of the immersed infusion line tip.
To determine a relative value for the static syringe pump-infusion line compliance, retrograde aspiration volume after lowering the syringe pump by 50 cm was measured while pump was in hold position.
Second, at steady state flow conditions zero-drug delivery time (ZDDT; time period between lowering of the syringe pump and reattainment of initial weight on the balance) was determined after lowering the pump by 50 cm below the level of the immersed infusion line tip. Experiments were performed at infusion rates of 4, 10, 20, 50, and 100 µL·hr -1 in the PMV infusion pump, and at 100, 200, 500 and 1000 µL·hr -1 in the conventional syringe pump infusion line assembly.
Third, to study the effect of infusion line compliance on ZDDT at very low infusion rates, measurements with the PMV infusion pump were repeated by replacing the original Panomat® infusion line by a soft, more compliant 150 cm infusion line (Injectomat® infusion line; Fresenius AG, Bad Homburg, Germany).
All experiments were performed at 22-24°C ambient temperature in duplicates using two individual pumps, and two different syringes with infusion lines of each brand (eight measurements).
Data analysis
Static compliance and ZDDT were compared across the three syringe pump infusion line assemblies by Wilcoxon-Mann-Whitney-Test. Data are presented as mean ± SD. A P value of less than 0.05 was considered statistically significant. R Re es su ul lt ts s Continuous flow data of the PMV infusion pump are presented in Table I . Static compliance differed significantly between the two syringe pump types and the two infusion line assemblies (PMV pump with two different extension lines). The static compliance of the PMV device with its original infusion line was 11 times smaller than that of the conventional infusion pump assembly (P < 0.005). A six-fold increase was measured when the original infusion line of the PMV system was replaced by the Injectomat® infusion line (P < 0.005; Table II) . ZDDT for the PMV infusion pump with the original infusion line at 4 µL·hr -1 infusion rate ranged from 38.4 ± 7.3 min and increased to 166.1 ± 12.8 min when the Injectomat® infusion line was used (Table II) . At 100 µL·hr -1 with the original infusion line, ZDDT was about 19 times shorter compared to the conventional syringe pump infusion line assembly (1.5 ± 0.5 min vs 28.5 ± 5.0 min; P < 0.005) and increased to 4.0 ± 0.9 min with the Injectomat® infusion line (P < 0.001).
D Di is sc cu us ss si io on n The present study investigates the overall performance of a special-purpose micro-volumetric infusion pump at very low flow rates and after vertical displacement of the infusion pump assembly. Since absolute amounts of fluid delivery are of less importance in intensive care medicine than continuity of drug administration, conventional syringe pumps are primarily designed as titration elements particularly when used with inotropic, vasoactive, and endocrine drugs. Conversely, absolute amounts at very low infusion rates have a higher priority than continuity of drug delivery for intrathecal drug administration (e.g., baclofen). The tested PMV infusion device provides very accurate fluid delivery even at smallest infusion rates (µL·hr -1 ) according to the manufacturers specifications of < 5% flow inaccuracy at maximum delivery rate (= 1000 µL·hr -1 ), and proportionally larger deviations at smaller flow rates. Thus the device is particularly suitable for continuous intrathecal drug administration, e.g., baclofen medication in children suffering from spasticity of cerebral origin.
Continuous fluid delivery from conventional syringe infusion pumps is known to be a critical issue after vertical displacement of the syringe pump infusion line assembly, and is caused by changes in hydrostatic pressure within the infusion system. 1, 4 Particularly at low infusion rates, these changes lead to prolonged gravitational siphoning of the infusion solution into the system when the pump device is lowered. Below 1 mL·hr -1 , drug delivery may be delayed or interrupted for several minutes up to hours after vertical displacement of the infusion pump.
5 ZDDT (time with suspended drug delivery) raises with decreasing infusion rates following roughly a 1/X ratio (e.g., halving the infusion rate doubles the ZDDT). 5 If the tested conventional syringe pump infusion line assembly, which proved to have the best performance compared to earlier investigations, had been used for the above mentioned intrathecal drug administration at 4 µL·hr -1 , and assuming that halving the infusion rate doubles the ZDDT, a calculated ZDDT of approximately 13 hr would have resulted. [6] [7] [8] Besides interruption of drug administration, it is con- ceivable that large ZDDTs and retrograde aspiration of blood into a catheter carries the potential risk of accidental catheter occlusion. Several characteristics may explain the flow accuracy, the outstanding low system compliance and performance after vertical displacement of the PMV infusion pump system:
Instead of the widely used 50-mL syringes in conventional syringe pumps the PMV infusion device is provided with a specially designed 10-mL plastic cartridge. This smaller size has reduced compressible areas, and the avoidance of a compressible rubber seal plunger decreases syringe compliance substantially. 6, 8 Furthermore, the threaded metallic piston rod, the firm fit of the drive nut into the cartridge body (closed with a screw adapter) and the syringe driver form a stiff and low compliant functional unit. 7 Infusion line compliance may further influence pump performance substantially. 9 The importance of using the original stiff, low compliant tube extension set with a very small inner diameter was demonstrated by the four-fold increase in ZDDT when it was replaced by the soft, more compliant Injectomat® infusion line (Table II) . 9 The design of the tested PMV infusion device results in minimal mechanical gaps, a low overall system compliance and contributes to its optimized functional performance. 10 Even though this device may be very advantageous in terms of high flow accuracy and low susceptibility to vertical displacement several points with respect to its potential use in pediatric anesthesia and intensive care medicine must be mentioned: First, in case of accidental occlusion, the device's cut-out pressure is set at 4 bar, resulting in a maximum back-up bolus of 80 µL (manufacturer's specifications). This threshold appears excessively high but confirms our measurements of the system compliance (0.02 µL·cm -1 H 2 O). Second, due to the specific pump motor design an appropriate liquid bolus is released stepwise every three minutes ( Figure  2 ). This fluid delivery strategy is not suitable for inotropic or vasoactive medication since their short half-life (usually one to two minutes) would result in a periodic discontinuity of the desired drug effect. Finally, although the small 10-mL cartridge contributes substantially to the advantages of this specific pump device it would require frequent refilling maneuvers if used for higher fluid delivery rates.
There are some limitations of the present study. First, measurements of start up delay and comparison of the performance after vertical syringe pump displacement at higher flow rates were not accessible to our evaluation because of the cyclic fluid release every three minutes in the PMV pump device. Second, even though some conventional infusion pumps may be loaded with smaller 10-mL syringes, we compared the 10-mL PMV infusion pump with a 50-mL syringe infusion pump, which represents the widely used, standard device in pediatric anesthesia and intensive care medicine.
In conclusion, the tested PMV infusion pump shows excellent flow accuracy as well as a low susceptibility to negative vertical displacement, and is therefore suitable for drug administration at very low flow rates (e.g., intrathecal as in the case described). The technology used in this pump carries potential implications for a new generation of syringe pumps for its use in pediatric and neonatal intensive care medicine and anesthesia.
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